-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 QV0FholDSauFsvxBD4jyOmE44k2+Yej2fmY8mldnXAAwxLNmUa+uMxD4H6MdAYi+
 ru0ePRbuZcSg7zYMPOgjRw==

<SEC-DOCUMENT>0001075880-05-000032.txt : 20050914
<SEC-HEADER>0001075880-05-000032.hdr.sgml : 20050914
<ACCEPTANCE-DATETIME>20050913211558
ACCESSION NUMBER:		0001075880-05-000032
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20050914
FILED AS OF DATE:		20050914
DATE AS OF CHANGE:		20050913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		051083343

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>asxannounc050914.txt
<TEXT>
UNITED STATES
SECURITIES	AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September2005

Novogen Limited
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes   No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
	82- ________________	.1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 14 September, 2005  By /s/Ronald Lea Erratt Company Secretary

ASX & MEDIA RELEASE
14 September 2005

NOVOGEN DRUG REDUCES CARDIOVASCULAR RISK IN HUMAN CLINICAL STUDY

A new cardiovascular drug developed by pharmaceutical company
Novogen Limited, has demonstrated significant reduction in blood
pressure and reduced arterial stiffness in a Phase Ib human
clinical trial.

The trial of the drug trans NV-04 has been completed at the
Baker Heart Research Institute in Melbourne, Australia.

The study tested a synthetic isoflavone metabolite,
trans NV-04.  This metabolite, an isoflavonoid compound
synthesised by Novogen, was administered orally to 25
middle-aged men and women who were overweight and also suffered
from at least two complications of fatness: abnormal blood fats;
high blood glucose; or raised blood pressure.

The trial was double-blind, so that neither subjects nor
investigators knew the order in which the test isoflavone or
a placebo were taken in a cross-over design in which the drug
or placebo was tested over consecutive periods each of 5 weeks.

Arterial stiffness, measured across the large arteries in the
chest and abdomen by a non-invasive technique, was significantly
reduced by the course of trans NV-04 treatment.  Blood pressures,
both systolic and diastolic, were also lowered significantly.

Principal investigator in the study and also a Director of
Novogen, Professor Paul Nestel said the trial confirmed that
isoflavonoid compounds exerted clinically beneficial effects
on the functioning of large arteries.

"In addition, the test drug was very well absorbed and had an
excellent safety profile", Professor Nestel said.

 'It is well known that arteries become stiff as people become
older or overweight, or as their blood pressure rises.

"With several risk factors for heart disease, stiffness of
arteries is often present and increases the likelihood of blood
pressure rising.

"The results of this study are encouraging in producing a range
of cardiovascular benefits without side effects, indicating a
potential for this to be used to avoid heart disease in large
numbers of healthy or at risk patients," Professor Nestel said.

Worsening of arterial stiffness or compliance is linked with
increased risk of future heart attacks.

Therefore it is expected that trials of drugs that lower arterial
stiffness will demonstrate a concomitant lowering of heart attack
risk.

Evidence for improved effects on arterial compliance is now
required by many regulatory bodies for registration of new drugs
where cardiovascular therapeutic claims are sought.

Novogen Research Director, Professor Alan Husband said previous
studies carried out by the Baker Heart Research Institute showed
that arterial stiffness could  also be reduced with naturally
occurring dietary isoflavones.

"The present study shows that metabolites formed in the body
from ingested isoflavones are highly active,"
Professor Husband said.

"This explains the success demonstrated by a number of Novogen's
synthetic isoflavonoid compounds in a range of indication areas."

Novogen is an Australian biopharmaceutical company specializing
in the development of therapeutics based on the isoflavonoid
chemical structure.  The Company is developing a range of
therapeutics across the fields of oncology, cardiovascular
disease and inflammatory diseases and phenoxodiol, its lead
anti-cancer agent is currently in advanced Phase II clinical
trialling. The Novogen group of companies includes the listed
subsidiary Marshall Edwards Inc. (Nasdaq: MSHL LSE-AIM:MSH).

More information on the Novogen Group can be found at
www.novogen.com and www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has
been investigated in clinical trials.  After the results of
these trials are submitted in a new drug application to
the FDA, the FDA must approve the drug as safe and effective
before marketing can take place.

Statements included in this press release that are not
historical in nature are "forward-looking statements"
within the meaning of the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. You should
be aware that our actual results could differ materially from
those contained in the forward-looking statements, which are
based on management's current expectations and are subject
to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval,
of our product candidates; uncertainties in clinical trial
results; our inability to maintain or enter into, and
the risks resulting from our dependence upon, collaboration
or contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our
inability to protect our patents or proprietary rights
and obtain necessary rights to third party patents and
intellectual property to operate our business; our inability
to operate our business without infringing the patents and
proprietary rights of others; general economic conditions;
the failure of any products to gain market acceptance; our
inability to obtain any additional required financing;
technological changes; government regulation; changes in
industry practice; and one-time events. We do not intend to
update any of these factors or to publicly announce the
results of any revisions to these forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Novogen Limited, + 61.2.9878 0088
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
